No connection

Search Results

HCTI vs INM

HCTI
Healthcare Triangle, Inc.
BEARISH
Price
$2.40
Market Cap
$2.8M
Sector
Healthcare
AI Confidence
95%
INM
InMed Pharmaceuticals Inc.
BEARISH
Price
$0.72
Market Cap
$2.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
HCTI
--
INM
--
Forward P/E
HCTI
-0.08
INM
-0.11
P/B Ratio
HCTI
0.14
INM
0.21
P/S Ratio
HCTI
0.21
INM
0.53
EV/EBITDA
HCTI
-1.29
INM
0.57

Profitability

Gross Margin
HCTI
13.12%
INM
29.73%
Operating Margin
HCTI
-74.26%
INM
-258.57%
Profit Margin
HCTI
-48.84%
INM
-170.07%
ROE
HCTI
-183.0%
INM
-97.2%
ROA
HCTI
-39.27%
INM
-49.77%

Growth

Revenue Growth
HCTI
44.6%
INM
-26.2%
Earnings Growth
HCTI
--
INM
--

Financial Health

Debt/Equity
HCTI
0.18
INM
0.06
Current Ratio
HCTI
2.03
INM
5.94
Quick Ratio
HCTI
1.94
INM
4.85

Dividends

Dividend Yield
HCTI
--
INM
--
Payout Ratio
HCTI
0.0%
INM
0.0%

AI Verdict

HCTI BEARISH

HCTI presents a classic value trap scenario, characterized by a stable Piotroski F-Score of 4/9 but catastrophic price action and fundamental decay. While the company shows strong top-line revenue growth of 44.6%, it is coupled with a disastrous ROE of -183% and an operating margin of -74.26%. The extreme discrepancy between the 52-week high ($7470) and current price ($2.40) indicates a total collapse in investor confidence or a massive corporate restructuring. Despite low debt and a healthy current ratio, the lack of profitability and negative earnings surprises make this a high-risk speculative asset.

Strengths
Strong YoY revenue growth of 44.60%
Low Debt/Equity ratio of 0.18
Healthy liquidity with a Current Ratio of 2.03
Risks
Catastrophic price performance (-99.9% 1Y change)
Severe negative profitability (Profit Margin -48.84%)
Extreme equity erosion (ROE -183%)
INM BEARISH

The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across nearly all fundamental health dimensions. While the current ratio is high (5.94), this is offset by a catastrophic profit margin of -170.07% and declining year-over-year revenue growth of -26.20%. The stock is in a clear long-term death spiral, with a 5-year price change of -100% and a technical trend score of 0/100. Without a pivot to profitability or a significant capital infusion, the business model appears unsustainable.

Strengths
Very low Debt/Equity ratio (0.06) indicating minimal long-term debt burden
Strong short-term liquidity with a Current Ratio of 5.94
Positive Gross Margin (29.73%) suggesting the core product has some inherent value
Risks
Critical financial health as evidenced by a 1/9 Piotroski F-Score
Severe operational inefficiency with an Operating Margin of -258.57%
Negative revenue growth (-26.20% YoY) indicating shrinking market share or demand

Compare Another Pair

HCTI vs INM: Head-to-Head Comparison

This page compares Healthcare Triangle, Inc. (HCTI) and InMed Pharmaceuticals Inc. (INM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile